Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolit...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/19/6114 |
| _version_ | 1797575662292172800 |
|---|---|
| author | Zakaria Alameddine Racha Abi Melhem Reem Dimachkie Hussein Rabah Hamed Chehab Michel El Khoury Faris Qaqish Dimitre Stefanov Suzanne El-Sayegh |
| author_facet | Zakaria Alameddine Racha Abi Melhem Reem Dimachkie Hussein Rabah Hamed Chehab Michel El Khoury Faris Qaqish Dimitre Stefanov Suzanne El-Sayegh |
| author_sort | Zakaria Alameddine |
| collection | DOAJ |
| description | Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolithiasis. We conducted a study to further investigate this association. Methods: The study used multiple logistic regression analysis to assess the association between the use of biologic drugs and nephrolithiasis. A <i>p</i>-value of <0.05 was considered statistically significant. SAS 9.4 was used for statistical analysis. Results: The final sample consisted of 22,895 cases, among which 5603 (24.51%) were receiving at least one biologic drug. The biologic drugs received were as follows: Adalimumab 2437 (10.66%), Infliximab 1996 (8.73%), Vedolizumab 1397 (6.11%), Ustekinumab 1304 (5.70%); Tofacitinib, 308 (1.35%); Certolizumab, 248 (1.08%); and Golimumab, 121 (0.53%). There were 1780 (7.74%) patients with Nephrolithiasis: 438 (8.0%) patients were receiving biologic treatment. We found that the use of Vedolizumab (OR = 1.307, 95% CI 1.076–1.588, <i>p</i> = 0.0071) increased the odds of Nephrolithiasis by 31%. Conclusion: Vedolizumab use was associated with an increased risk of nephrolithiasis. The use of two or more biologic drugs also increased the risk compared to no biologic treatment. |
| first_indexed | 2024-03-10T21:42:24Z |
| format | Article |
| id | doaj.art-109db41610b84a388a63f604c1e80dd6 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T21:42:24Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-109db41610b84a388a63f604c1e80dd62023-11-19T14:34:16ZengMDPI AGJournal of Clinical Medicine2077-03832023-09-011219611410.3390/jcm12196114Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic TreatmentZakaria Alameddine0Racha Abi Melhem1Reem Dimachkie2Hussein Rabah3Hamed Chehab4Michel El Khoury5Faris Qaqish6Dimitre Stefanov7Suzanne El-Sayegh8Department of Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, USADepartment of Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, USADepartment of Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, USADepartment of Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, USADepartment of Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, USADepartment of Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, USADepartment of Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, USABiostatistics Unit, Feinstein Institutes for Medical Research, 350 Community Dr, Manhasset, NY 11030, USADepartment of Internal Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, USAIntroduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolithiasis. We conducted a study to further investigate this association. Methods: The study used multiple logistic regression analysis to assess the association between the use of biologic drugs and nephrolithiasis. A <i>p</i>-value of <0.05 was considered statistically significant. SAS 9.4 was used for statistical analysis. Results: The final sample consisted of 22,895 cases, among which 5603 (24.51%) were receiving at least one biologic drug. The biologic drugs received were as follows: Adalimumab 2437 (10.66%), Infliximab 1996 (8.73%), Vedolizumab 1397 (6.11%), Ustekinumab 1304 (5.70%); Tofacitinib, 308 (1.35%); Certolizumab, 248 (1.08%); and Golimumab, 121 (0.53%). There were 1780 (7.74%) patients with Nephrolithiasis: 438 (8.0%) patients were receiving biologic treatment. We found that the use of Vedolizumab (OR = 1.307, 95% CI 1.076–1.588, <i>p</i> = 0.0071) increased the odds of Nephrolithiasis by 31%. Conclusion: Vedolizumab use was associated with an increased risk of nephrolithiasis. The use of two or more biologic drugs also increased the risk compared to no biologic treatment.https://www.mdpi.com/2077-0383/12/19/6114nephrolithiasisinflammatory bowel diseasebiologicsvedolizumaburolithiasisstone |
| spellingShingle | Zakaria Alameddine Racha Abi Melhem Reem Dimachkie Hussein Rabah Hamed Chehab Michel El Khoury Faris Qaqish Dimitre Stefanov Suzanne El-Sayegh Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment Journal of Clinical Medicine nephrolithiasis inflammatory bowel disease biologics vedolizumab urolithiasis stone |
| title | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
| title_full | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
| title_fullStr | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
| title_full_unstemmed | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
| title_short | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
| title_sort | risk of nephrolithiasis in patients with inflammatory bowel disease receiving biologic treatment |
| topic | nephrolithiasis inflammatory bowel disease biologics vedolizumab urolithiasis stone |
| url | https://www.mdpi.com/2077-0383/12/19/6114 |
| work_keys_str_mv | AT zakariaalameddine riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT rachaabimelhem riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT reemdimachkie riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT husseinrabah riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT hamedchehab riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT michelelkhoury riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT farisqaqish riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT dimitrestefanov riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT suzanneelsayegh riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment |